Investors

May 13, 2020

Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%

May 12, 2020

Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19

May 6, 2020

Veru to Report Fiscal 2020 Second-Quarter Financial Results, Host Conference Call on May 13th

May 5, 2020

Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program

Feb 26, 2020

Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

Feb 12, 2020

Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%

Feb 5, 2020

Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th

Jan 21, 2020

Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020

Jan 13, 2020

Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy

Dec 12, 2019

Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%

Dec 5, 2019

Veru to Report Fiscal 2019 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 12th

Oct 2, 2019

Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes